JPGN reports
Cure8 research brief
Why This Matters
The report suggests tofacitinib (a JAK inhibitor), alone or combined with ustekinumab, could be an effective option for some infants with treatment-refractory IOIBD — a population with few evidence-based alternatives. If confirmed, this could expand options for clinicians treating very-early-onset severe IBD.
Who Should Pay Attention
Pediatric IBD clinicians, pediatric gastroenterologists, parents and caregivers of infants with very-early-onset or treatment-refractory IBD, and researchers planning pediatric IBD trials.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This is a very small, retrospective series focused on infantile-onset IBD — a rare and severe form of very-early-onset disease. The patients received combination therapy with a JAK inhibitor (tofacitinib) plus ustekinumab after other treatments failed, and the abstract reports remissions and no adverse events in these four cases.
Because the extraction is abstract-level, details such as dosing, duration, selection criteria, long-term safety, and follow-up are not provided here. The authors conclude that larger prospective studies are needed to define the role of JAK inhibitors in this population.
Keep In Mind
Findings are from a retrospective chart review of four patients described at abstract level. Important details (dosing, duration, inclusion/exclusion, follow-up length) are not available in the abstract; larger prospective studies are needed. The report did not find monogenic causes in these patients, which may limit generalizability to genetically-driven IOIBD.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationJPGN reports
AuthorsMahajan S, Wysocki C, Gurram B
Study typeJournal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedApr 27, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
AbbVie (ABBV): 10 Best Low Risk Stocks to Buy in 2026
New trial and real-world data about Skyrizi and Rinvoq could affect treatment options and conversations about long-term outcomes for people with Crohn’s disease or ulcerative colitis. Investors’ coverage can increase...
Efficacy and Safety of Low-Dose Upadacitinib Combined With Ustekinumab in the Treatment of Refractory Crohn's Disease
This study examines a combination of ustekinumab plus low‑dose upadacitinib for patients with refractory Crohn’s disease — a group with limited options after failing anti‑TNF and single‑agent therapy. Results could...
Sequential Biologic, Small-Molecule, and GLP-1 Analogue Therapy in Postcolectomy Enteritis With High Output Stoma.
People with ulcerative colitis who have had colectomy can rarely develop inflammation of the small intestine and high-output stomas that are hard to control.